BofA/Merrill Lynch Downgrades Puma Biotechnology (PBYI) to Underperform

November 2, 2018 9:18 AM EDT Send to a Friend
BofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login